Hormone Therapy

Top Story

Discontinuation of postmenopausal hormone therapy elevates cardiac, stroke death risk

November 16, 2017

Read the Perspective from JoAnn V. Pinkerton, MD, NCMP

In the first year after discontinuation of postmenopausal hormone therapy, the risk for cardiac and stroke death increases, particularly among women aged younger than 60 years, according to findings published in Menopause.

“Associations between the long-term use of postmenopausal hormone therapy and risks of cardiovascular diseases have been studied for decades. The data are not uniform, perhaps partly due to differences in hormone therapy regimens and study populations,” Minttu M. Venetkoski, MD, from the department of obstetrics and gynecology at the University of Helsinki and Helsinki University Hospital, Finland, and colleagues wrote.

In the Journals Plus

Growth hormone therapy does not affect CV risk factors in young adults born small for gestational age

November 10, 2017
Children born small for gestational age treated with growth hormone therapy did not experience any negative effects on cardiometabolic health in the 5 years after…
In the Journals Plus

Estradiol therapy may benefit working memory in postmenopausal women

November 7, 2017
Working memory for short-term cognitive tasks after menopause may be protected with estradiol therapy in women, according to study findings published in The Journal of
Meeting News

‘Significantly higher’ side effects with pellet vs. FDA-approved HT

October 17, 2017
PHILADELPHIA — Compared with postmenopausal women using FDA-approved hormone therapy, those treated with estradiol and/or testosterone pellet therapy experienced…
More Headlines »

Early Treatment of Diabetic Retinopathy and Diabetic Macular Edema: Optimal Use of Anti-VEGF Therapy for Vision Preservation and Restoration

This activity is supported by an educational grant from Genentech, Inc.

Diabetic retinopathy (DR) and diabetic macular edema (DME) are 2 of the most common causes of blindness among…
More »
Meeting News Coverage

VIDEO: Testosterone Trials results announcement met with anticipation

April 7, 2016
More »
Resource Centers



Rapid Response from Austin: Expanding Options in Type 2 Diabetes Management

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Approximately 150 million people worldwide have diabetes mellitus and this number is expected to double by 2025…
More »